87. POGO Letter to NIH on Ghostwriting Academics [Internet]. Project On Government Oversight. [cited 2012 Mar 24]. Available from: http://www.pogo.org/pogo-files/letters/publichealth/ ph-iis-20101129.html
88. http://www.nytimes.com/2010/11/30/business/30drug.html
89. http://pogoblog.typepad.com/pogo/gw-attachment-e.html
90. Lacasse JR, Leo J. Ghostwriting at Elite Academic Medical Centers in the United States. PLoS Med. 2010 Feb 2;7(2):e1000230.
91. Matheson A. How Industry Uses the ICMJE Guidelines to Manipulate Authorship And How They Should Be Revised. PLoS Med. 2011;8(8):e1001072.
92. Dyer O. Journal rejects article after objections from marketing department. BMJ. 2004 Jan 31;328(7434):244-b-244.
93. Fugh-Berman A, Alladin K, Chow J. Advertising in Medical Journals: Should Current Practices Change? PLoS Med. 2006 May 2;3(6):e130.
94. Becker A, Dorter F, Eckhardt K, Viniol A, Baum E, Kochen MM, et al. The association between a journal’s source of revenue and the drug recommendations made in the articles it publishes. CMAJ. 2011 Feb 28 Available from: http://www.cmaj.ca/content/early/2011/02/28/cmaj.100951
95. Smith R. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. PLoS Med. 2005 May 17;2(5):e138.
96. AUTH/2424/8/11 and AUTH/2425/8/11 General Practitioner v Boehringer Ingelheim and Lilly. Available from: http://www. pmcpa.org.uk/?q=node/998.
97. Handel AE, Patel SV, Pakpoor J, Ebers GC, Goldacre B, Ramagopalan SV. High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ. 2012 Jun 28;344(jun28 1):e4212-e4212.
98. Jefferson T, Di Pietrantonj C, Debalini MG, Rivetti A, Demicheli V. Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. BMJ. 2009 Feb 12;338(feb12_2):b354.
99. http://classic.thescientist.com/blog/display/55679/
100. http://elsevier.com/wps/find/authored newsitem.cwshome/ companynews05_01203
101. Bowman MA. The impact of drug company funding on the content of continuing medical education. Mobius: A Journal for Continuing Education Professionals in Health Sciences. 1986 Jan 1;6(1):66-9.
102. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. Journal of Continuing Education in the Health Professions. 1988 Jan 1;8(1):13–20.
103. The Carlat Psychiatry Blog: PRMS [Internet]. [cited 2012 Mar 31]. Available from: http://carlatpsychiatry.blogspot.co.uk/ search/label/PRMS
104. Stephan Sahm, ‘Of mugs, meals and more: the intricate relations between physicians and the medical industry.,’ Medicine, health care, and philosophy (2011).
105. Avorn J, Choudhry NK. Funding for Medical Education: Maintaining a Healthy Separation From Industry. Circulation. 2010 May 25;121(20):2228-34.
106. L. Garattini et al., ‘Continuing Medical Education in six European countries: A comparative analysis,’ Health policy 94, no. 3 (2010): 246–254.
107. Eckardt VF. Complimentary journeys to the World Congress of Gastroenterology an inquiry of potential sponsors and beneficiaries. Z Gastroenterol. 2000 Jan;38(1):7-11.
108. http://www.pmlive.com/find_an_article/allarticles/categories/ General/2011/november_2011/features/cme_continuing_medic al_education_change
109. US Senate Committee on Finance. Committee Staff Report to the Chairman and Ranking Member: Use of Educational Grants by Pharmaceutical Manufacturers. Washington, DC: Government Printing Office; 2007.
110. Hensley S, Martinez B. To sell their drugs, companies increasingly rely on doctors. Wall St J (East Ed). 2005 Jul 15;A1,A2.
111. Tabas JA, Boscardin C, Jacobsen DM, Steinman MA, Volberding PA, Baron RB. Clinician Attitudes About Commercial Support of Continuing Medical Education: Results of a Detailed Survey. Arch Intern Med. 2011 May 9;171(9):840-6.
112. Amy T Wang et al., ‘Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review,’ BMJ 340, no. 18 (March 18, 2010): c1344.
113. Rothman KJ, Evans S (2005) Extra scrutiny for industry funded trials. BMJ 331: 1350-1351
114. Wager E, Mhaskar R, Warburton S, Djulbegovic B (2010) JAMA Published Fewer Industry-Funded Studies after Introducing a Requirement for Independent Statistical Analysis. PLoS ONE 5(10): e13591. doi:10.1371/journal.pone.0013591
115. Chalmers TC, Frank CS, Reitman D. Minimizing the Three Stages of Publication Bias. JAMA. 1990 Mar 9;263(10):1392-5.
116. Samena Chaudhry et al., ‘Does declaration of competing interests affect readers’ perceptions? A randomised trial,’ BMJ 325, no. 7377 (December 14, 2002): 1391–1392. (below).
117. Reporting of Conflicts of Interest in Metaanalyses of Trials of Pharmacological Treatments. JAMA. 2011;305(10):1008–1017. doi: 10.1001/jama.2011.257
118. Loewenstein G, Sah S, Cain DM. The Unintended Consequences of Conflict of Interest Disclosure. JAMA. 2012 Feb 15;307(7):669-70.
119. Cain, D. M., Loewenstein, G.,& Moore, D. A. (2005). The dirt on coming clean: perverse effects of disclosing conflicts of interest. Journal of Legal Issues, 34, 1e25.
120. Campbell EG, Weissman JS, Ehringhaus S et al. Institutional academic industry relationships. JAMA 2007;298:1779-86.
121. http://www.propublica.org/series/dollars-for-docs
122. http://www.propublica.org/article/doctors-dine-on-drugcompanies-dime
123. http://www.propublica.org/article/dollars-for-docs-sparkspolicy-rewrite-at-colorado-teaching-hospitals
124. http://www.propublica.org/article/medical-schools-plug-holesin-conflictof-interest-policies
125. http://www.propublica.org/article/dollars-to-doctorsphysiciandisciplinary-records/single
126. http://www.propublica.org/article/drugcompanies-reducepayments-to-doctors-as-scrutiny-mounts
127. http://www.propublica.org/article/piercing-the-veil-moredrugcompanies-reveal-payments-to-doctors
128. Carlowe J. Drug companies to declare all payments made to doctors from 2012. BMJ. 2010 Nov 5;341(nov051):c6290-c6290.
129. Tuffs A. Two doctors in Germany are convicted of taking bribes from drug company. BMJ. 2010 Nov 9;341(nov092):c6359-c6359.
130. http://www.fcaalert.com/2011/02/articles/dojhhs-releases-newstatistics-about-sealed-qui-tam-cases/
131. Sweet M. Experts criticise industry sponsorship of articles on health policy in Australian newspaper. BMJ. 2011 Oct 25;343(oct25 2):d6903-d6903.
132. http://www.pmcpa.org.uk/?q=node/499
133. http://www.propublica.org/documents/item/87376-heartrhythm-society
134. http://www.propublica.org/article/medical-groups-shy-aboutdetailing-industry-financial-support
135. JP Kassirer. On the Take: How Medicine’s Complicity with Big Business Can Endanger Your Health. 1st ed. Oxford University Press, USA; 2004.
136. http://www.eatright.org/corporatesponsors/.
137. JP Kassirer. On the Take: How Medicine’s Complicity with Big Business Can Endanger Your Health. 1st ed. Oxford University Press, USA; 2004, p105.
138. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002 Feb 6;287 (5):612-7.Заключение: усовершенствованные данные
1. Department of Justice, Office of Public Affairs. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data. Monday, July 2, 2012.http://www.justice.gov/opa/pr/2012/July/12-civ842.html
2. Glaxo executives cited in case now lead Sanofi, Actelion. Bloomberg News, 3/7/12. http://www.businessweek.com/news/ 201207-03/glaxo-executives-cited-in-case-now-lead-sanofiactelion
3. Inpharm 4/7/12. GSK ruling: another failing, but will the industry learn? http://www.inpharm.com/news/173307/gskrulinganother-failing-will-industry-learn
4. Glaxo Agrees to Pay $3 Billion in Fraud Settlement. New York Times, July 2 2012. http://www.nytimes.com/2012/07/03/ business/glaxosmithkline-agrees-to-pay-3-billion-in-fraudsettlement.html
5. Level playing field push to continue despite setback 8 December 2011. Medicines Australia. http://medicinesaustralia. com. au/2011/12/08/level-playing-field-push-to-continue-despitesetback/
6. Drug companies to work with CCGs on care pathways and case finding under DH-backed scheme. Pulse, 28 May 2012, http://www.pulsetoday.co.uk/ newsarticle-content/-/article_ display_ list/14029608/drugcompanies-to-work-with-ccgs-oncarepathways-and-case-finding-under-dh-backed-scheme.
7. Bosch X, Esfandiari B, McHenry L. Challenging Medical Ghostwriting in US Courts. PLoS Med. 2012 Jan 24;9(1): e1001163.Послесловие: что случилось потом?
1. The citation here is, for obvious reasons, ‘personal communication’. The email from the academic continued: ‘From my perspective, I don’t think we should be anything but indignant!’
2. Davis C, Abraham J. Is there a cure for corporate crime in the drug industry? BMJ. 2013;346:f755.
3. Gale EAM. Post-marketing studies of new insulins: sales or science? BMJ. 2012;344:e3974.
4. Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012;345:e4348.
5. Svensson S, Menkes DB, Lexchin J. Surrogate Outcomes in Clinical Trials: A Cautionary Tale. JAMA Intern Med. 2013;173(8):611612.
6.„JAMA, Integrity, Accessibility, and Social vs. Scientific Peer Review“. Emergency Medicine Literature of Note, Feb 26, 2013.
7. Abbasi, K. Blood on our hands: seeing the evil in inappropriate comparators. J R Soc Med. 2013 January;106(1): 1.
8. Inside Health, BBC Radio 4, January 2013.
9. Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW, et al. (2013) Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis. PLoS Med 10(3): e1001407. doi:10.1371/journal.pmed.1001407
10. Ioannidis JPA. How Many Contemporary Medical Practices Are Worse Than Doing Nothing or Doing Less? Mayo Clinic Proceedings. 2013 Aug;88(8):779-81.
11. Zarin DA, Tse T. Trust but Verify: Trial Registration and Determining Fidelity to the Protocol. Ann Intern Med. 2013;159(1): 65–67.
12. Rosenthal R, Dwan K. Comparison of randomized controlled trial registry entries and content of reports in surgery journals. Ann Surg. 2013 Jun;257(6):1007-15.
13. Zetterqvist AV, Mulinari S (2013) Misleading Advertising for Antidepressants in Sweden: A Failure of Pharmaceutical Industry Self-Regulation. PLoS ONE 8(5): e62609. doi:10.1371/journal. pone.0062609
14. Mintzes B, Lexchin J, Sutherland JM, Beaulieu M-D, Wilkes MS, Durrieu G, et al. Pharmaceutical Sales Representatives and Patient Safety: A Comparative Prospective Study of Information Quality in Canada, France and the United States. J Gen Intern Med. 2013 Apr 5.
15. http://dailycaller.com/2013/04/27/critics-see-conflict-ofinterestas-obama-admin-advises-doctors-on-prescriptions/
16. http://www.propublica.org/article/pay-to-prescribe-twodozendoctors-named-in-novartis-kickback-case
17. Bosch X, Hernandez C; Pericas JM, Doti P. Ghostwriting Policies in HighImpact Biomedical Journals: A Cross-Sectional Study. JAMA Intern Med. 2013;173(10):920–921.
18. Nancarrow, CM. Editorial Policies to Ensure Honesty and Transparency: Comment on „Ghostwriting Policies in HighImpact Biomedical Journals: A Cross-Sectional Study“. JAMA Intern Med. 2013;173(10):921–922.
19. Persaud N. Questionable content of an industry-supported medical school lecture series: a case study. J Med Ethics. doi:10.1136/ medethics-2013-101343
20. India’s poor duped into clinical drug trials. Economic Times, 7th July 2013.
21. Vedula SS, Li T, Dickersin K. Differences in Reporting of Analyses in Internal Company Documents Versus Published Trial Reports: Comparisons in IndustrySponsored Trials in Off-Label Uses of Gabapentin. PLoS Med. 2013 Jan 29;10(1):e1001378.
22. Sample, Ian. Big pharma mobilising patients in battle over drugs trials data. Guardian, 21st July 2013.
23. http://www.alltrials.net/2013/responses-to-leaked-memo/
24. Huser V, Cimino JJ (2013) Linking ClinicalTrials.gov and PubMed to Track Results of Interventional Human Clinical Trials. PLoS ONE 8(7): e68409. doi:10.1371/journal.pone.0068409
25. Schroll JB, Bero L, G0tzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ 2013;346:f2231.
26. Wieseler B, McGauran N, Kerekes MF, Kaiser T. Access to regulatory data from the European Medicines Agency: the times they are a-changing. Syst Rev. 2012 Oct 30;1:50.
27. Little RJ, D’Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The Prevention and Treatment of Missing Data in Clinical Trials. N Engl J Med. 2012; 367:1355–1360.
28. Mathieu S, Chan A-W, Ravaud P (2013) Use of Trial Register Information during the Peer Review Process. PLoS ONE 8(4): e59910. doi:10.1371/journal.pone.0059910
29. Prayle AP, Hurley MN, Smyth AR (2012) Data from: Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. Dryad Digital Repository. doi:10.5061/dryad.j512f21p
30. Simmonds MC, Brown JVE, Heirs MK, Higgins JPT, Mannion RJ, Rodgers MA, et al. Safety and Effectiveness of Recombinant Human Bone Morphogenetic Protein-2 for Spinal Fusion: A Meta-analysis of Individual-Participant Data. Ann Intern Med. 2013;158(12):877–889.
Примечания